Trial Radar IA
Lo studio clinico NCT07396766 (BREASTChoice) per Cancro al seno, Neoplasie al seno è in arruolamento. Consulti la vista a schede del Radar degli Studi Clinici e gli strumenti di scoperta IA per tutti i dettagli. Oppure, ponga pure una domanda qui.
Un studio corrisponde ai criteri del filtro
Vista a schede
Torna alla ricerca

Dissemination of BREASTChoice AIM1-B 20

In arruolamento
I dettagli dello studio clinico sono disponibili principalmente in inglese. Tuttavia, Trial Radar IA può essere d'aiuto! Basta cliccare su 'Spiega lo studio' per visualizzare e discutere le informazioni sullo studio nella lingua selezionata.
La sperimentazione clinica NCT07396766 (BREASTChoice) è uno studio interventistico per Cancro al seno, Neoplasie al seno, attualmente in arruolamento. Avviato il 1 ottobre 2025, prevede di arruolare 20 partecipanti. Sotto la guida di UNC Lineberger Comprehensive Cancer Center, dovrebbe concludersi entro il 20 gennaio 2029. I dati più recenti da ClinicalTrials.gov sono stati aggiornati l'ultima volta il 9 febbraio 2026.
Sommario breve
This registration covers only Aim 1b, which focuses on testing usability. The study will include 20 participants who are breast cancer patients. Participants will be observed using the tool on their mobile devices, and their experience will be evaluated using a "think-aloud" method to capture their thoughts and reactions. Interviews will include open-ended questions about the content and format of the decision aid, w...Mostra di più
Descrizione dettagliata
This study is part of a larger project that will update and adapt an existing online decision tool called BREASTChoice. The project includes interviews and user testing with breast cancer survivors, interviews with medical experts, and updates to the website design.

Breast reconstruction after a mastectomy is an important part of breast cancer treatment. It can help restore quality of life and body image, which are ...

Mostra di più
Titolo ufficiale

Dissemination of a Breast Reconstruction Decision Tool Through Social Media and Online Communities- AIM1-B

Patologie
Cancro al senoNeoplasie al seno
Altri ID dello studio
Numero NCT
NCT07396766
Data di inizio (effettiva)
2025-10-01
Ultimo aggiornamento pubblicato
2026-02-09
Data di completamento (stimata)
2029-01-20
Arruolamento (previsto)
20
Tipo di studio
Interventistico
FASE
N.D.
Stato
In arruolamento
Parole chiave
web-based patient decision aid
BREASTChoice
Scopo principale
Ricerca sui servizi sanitari
Allocazione
N.D.
Modello di intervento
A gruppo singolo
Mascheramento
Nessuno (studio in aperto)
Bracci / Interventi
Gruppo/Braccio di partecipantiIntervento/Trattamento
SperimentaleBreast cancer survivors
Breast cancer survivors.
Questionario di base
Participants will be screened and share demographic information during screening. If eligible and screened in, the interviewer will send the self-administered pre-survey Decision Quality Index (DQI).
Intervista semi-strutturata
Participants will participate in a semi-structured interview and review of the adapted BREASTChoice tool.
Post Survey
Participants will take the post-survey to assess breast reconstruction decision quality.
Esito primario
Misure di esitoDescrizione della misuraArco temporale
Change in breast reconstruction knowledge
This is knowledge based patient-reported outcome measure uses the Breast Cancer Reconstruction Decision Quality Instrument (DQI). DQ is a 9-item patient-reported measure designed to assess how well patients are informed about breast reconstruction options following breast cancer treatment. The instrument consists of multiple-choice questions with factual, correct answers related to breast reconstruction. Decision quality is quantified as a knowledge score, reflecting the extent to which patients understand key information necessary to make informed reconstruction decisions. Scores range from 0% to 100%. The total score is calculated by summing the number of correctly answered items and dividing by the total number of questions (9), with higher scores indicating greater knowledge and higher decision quality.
Up to1 week
Assistente alla partecipazione
Criteri di eleggibilità

Inclusions Criteria To participate in this study, a subject must meet all the eligibility criteria outlined below.

  • Age ≥ 18 years at the time of consent
  • Able to read and speak English.
  • Have had surgery, such as a mastectomy or lumpectomy, to remove some or all of their breast or breasts.
  • Breast surgery occurred within the past 8 years.
  • Breast surgery was due to a diagnosis of breast cancer, ductal carcinoma in situ, or risk of future breast cancer, by participant report.
  • Sex was assigned "Female" at birth

• Individuals with self-reported or observed unstable medical or psychiatric conditions precluding informed consent or participation in the study will be excluded.

UNC Lineberger Comprehensive Cancer Center logoUNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI) logoIstituto nazionale dei tumori, Estados Unidos
Contatti principali dello studio
Contatto: Victoria Triana, 919-966-4320, [email protected]
Contatto: Kathryn A Chetwynd, 919-966-4320, [email protected]
1 Centri dello studio in 1 paesi

North Carolina

The University of North Carolina, Chapel Hill, North Carolina, 27599, United States
Kathryn A Chetwynd, Contatto, 919-966-4320, [email protected]
Clara Lee, MD, Investigatore principale
In arruolamento